Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538]

Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538]

Bibliographic Details
Main Authors:	Lei Zhao, Nijia Chang, Lei Shi, Fengyi Li, Fanglin Meng, Xiaohui Xie, Zhe Xu, Fusheng Wang
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Series:	Heliyon
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844022026925

Similar Items

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
by: De-Zhen Guo, et al.
Published: (2023-02-01)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
by: Lijun Wang, et al.
Published: (2023-02-01)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
by: Hongyu Gong, et al.
Published: (2023-03-01)

Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium
by: Ning S, et al.
Published: (2023-09-01)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022-11-01)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
by: Nan Zhou, et al.
Published: (2023-10-01)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
by: Shu Zhao MD, et al.
Published: (2022-10-01)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
by: Gan L, et al.
Published: (2023-04-01)

A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma
by: Yinhua Gong, et al.
Published: (2023-05-01)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
by: Wenzhe Fan, et al.
Published: (2023-01-01)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
by: Jinfeng Wang MM, et al.
Published: (2023-05-01)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
by: Amit G. Singal, et al.
Published: (2023-01-01)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
by: I-Cheng Lee, et al.
Published: (2022-10-01)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021-01-01)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023-09-01)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024-03-01)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
by: Shigeki Yano, et al.
Published: (2023-11-01)

Efficacy of radiation plus transarterial chemoembolization and lenvatinib in hepatocellular carcinoma with portal vein tumor thrombus
by: Aoran Dong, et al.
Published: (2023-12-01)

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
by: Takenori Ichimura, et al.
Published: (2023-03-01)

Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis
by: Xiao‐Hui Wang, et al.
Published: (2023-03-01)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
by: Xiaoyan Ding, et al.
Published: (2022-07-01)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
by: Kei Amioka, et al.
Published: (2022-01-01)

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
by: Thaninee Prasoppokakorn, et al.
Published: (2022-01-01)

Efficacy and safety of anti-PD-1 monotherapy anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
by: Qingyan Liu, et al.
Published: (2023-10-01)

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
by: Xu Chang, et al.
Published: (2024-04-01)

Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study
by: Haohao Lu, et al.
Published: (2024-01-01)

Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery
by: Xudan Wang, et al.
Published: (2023-12-01)

Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways
by: Xijing Yan, et al.
Published: (2023-11-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
by: Xiaozhun Huang, et al.
Published: (2021-11-01)

Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases
by: Kai Peng, et al.
Published: (2023-12-01)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.
by: Yoshikazu Tateai, et al.
Published: (2023-01-01)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
by: Yoshikazu Tateai, et al.
Published: (2023-01-01)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
by: Tingting Shi, et al.
Published: (2021-12-01)

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
by: Tao M, et al.
Published: (2023-07-01)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
by: Xiaoping He, et al.
Published: (2022-05-01)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
by: Yunchao Wang, et al.
Published: (2023-01-01)

Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not
by: Kenji Imai, et al.
Published: (2024-01-01)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
by: Chang X, et al.
Published: (2023-06-01)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
by: Fucun Xie, et al.
Published: (2022-12-01)